帕博利珠单抗一线治疗PD-L1阳性晚期非小细胞肺癌:一项1期试验
在KEYNOTE-001开放标签1b期试验中,101例未接受过治疗的PD-L1阳性(≥1%染色)晚期非小细胞肺癌患者随机接受帕博利珠单抗2或10 mg/kg每3周或每2周静脉给药。客观缓解率为27%(27/101,95%CI 18-37),中位总生存期为22.1个月(95%CI 17.1-27.2);PD-L1肿瘤比例评分≥50%的患者客观缓解率、12个月无进展生存率和12个月总生存率分别为51.9%、54%和85%,均高于总体人群的26.7%、35%和71%。
要点
- 帕博利珠单抗一线治疗PD-L1阳性晚期非小细胞肺癌的客观缓解率为27%,中位总生存期为22.1个月。
- PD-L1肿瘤比例评分≥50%的患者客观缓解率为51.9%,12个月总生存率为85%。
- 仅12例(11.9%)患者发生3/4级治疗相关不良事件,无治疗相关死亡。
核心结论
- 帕博利珠单抗为PD-L1表达的未接受过治疗的晚期非小细胞肺癌提供有前景的长期总生存获益,安全性可控,在肿瘤比例评分≥50%的患者中疗效最佳。
研究设计与样本
- 开放标签1b期KEYNOTE-001试验(ClinicalTrials.gov,NCT01295827),纳入肿瘤表达PD-L1(≥1%染色,采用原型检测法评估)的未接受过治疗的晚期非小细胞肺癌患者,随机接受帕博利珠单抗2或10 mg/kg每3周或每2周静脉给药。
- 2013年3月1日至2015年9月18日期间,101例患者接受帕博利珠单抗2 mg/kg每3周(n=6)、10 mg/kg每3周(n=49)或10 mg/kg每2周(n=46)治疗。
- 所有接受至少1次帕博利珠单抗剂量的患者均按中央RECIST v1.1每9周评估疗效;采用治疗前肿瘤组织,通过临床检测法量化表达PD-L1的肿瘤细胞百分比作为肿瘤比例评分。
主要发现
- 101例患者中,27例(26.7%)肿瘤比例评分≥50%,52例(51.5%)为1%-49%,12例(11.9%)<1%。
- 总体客观缓解率为27%(27/101,95%CI 18-37),中位总生存期为22.1个月(95%CI 17.1-27.2)。
- PD-L1肿瘤比例评分≥50%的患者客观缓解率为51.9%(14/27,95%CI 32%-71%),12个月无进展生存率为54%,12个月总生存率为85%,均高于总体人群的26.7%(27/101,95%CI 18.4%-36.5%)、35%和71%。
- 仅12例(11.9%)患者发生3/4级治疗相关不良事件,无治疗相关死亡。
关键数值与推荐
- PD-L1阳性定义为肿瘤细胞≥1%染色,采用原型检测法评估。
- 帕博利珠单抗给药方案包括2 mg/kg每3周、10 mg/kg每3周或10 mg/kg每2周静脉给药。
- 疗效评估按中央RECIST v1.1每9周进行。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pembrolizumab improved survival as first- and second-line therapy compared with chemotherapy in patients with highly programmed death ligand 1 (PD-L1) expressing advanced non-small cell lung cancer (NSCLC). We report the long-term safety and clinical activity of pembrolizumab as first-line therapy for patients with advanced NSCLC and the correlation between PD-L1 expression and efficacy. PATIENTS AND METHODS: In the open-label phase 1b KEYNOTE-001 trial, treatment-naive patients with advanced NSCLC whose tumors expressed PD-L1 (≥1% staining, assessed using a prototype assay) were randomly assigned to intravenous pembrolizumab 2 or 10 mg/kg every 3 (Q3W) or 2 (Q2W) weeks. Response was assessed per central RECIST v1.1 every 9 weeks in all patients who received ≥1 pembrolizumab dose. Using pre-treatment tumor tissue, a clinical assay quantified the percentage of tumor cells expressing PD-L1 as tumor proportion score (TPS). RESULTS: Between 1 March 2013 and 18 September 2015, 101 patients received pembrolizumab 2 mg/kg Q3W (n = 6), 10 mg/kg Q3W (n = 49), or 10 mg/kg Q2W (n = 46). Of these, 27 (26.7%) had TPS ≥50%, 52 (51.5%) had TPS 1%-49%, and 12 (11.9%) had TPS <1%. The objective response rate (ORR) was 27% (27/101, 95% CI 18-37) and median overall survival was 22.1 months (95% CI 17.1-27.2). In patients with PD-L1 TPS ≥50%, ORR, 12-month PFS, and 12-month OS were higher [14/27 (51.9%; 95% CI 32%-71%), 54%, and 85%, respectively] than the overall population [27/101 (26.7%; 95% CI 18.4%-36.5%), 35%, 71%]. Pembrolizumab was well tolerated, with only 12 (11.9%) patients experiencing grade 3/4 treatment-related adverse events and no treatment-related deaths. CONCLUSIONS: Pembrolizumab provides promising long-term OS benefit with a manageable safety profile for PD-L1-expressing treatment-naive advanced NSCLC, with greatest efficacy observed in patients with TPS ≥50%. CLINICAL TRIAL NAME AND NUMBER: KEYNOTE-001 (ClinicalTrials.gov, NCT01295827).
引用
- Hui R, Garon EB, Goldman JW, et al. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. Ann Oncol. 2017. PMID: 28168303. doi:10.1093/annonc/mdx008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。